MENLO PARK, CA, Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, has raised $73 million in Series B financing.
The oversubscribed round was led by Viking Global Investors and included participation from Sherpalo Ventures and Hillspire. The funds will support Antheia as it brings its first pharmaceutical compound to market and scales up the production of a number of critical active pharmaceutical ingredients (APIs) and key starting materials (KSMs).
Antheia is unlocking the medicinal power of nature with synthetic biology. Through a novel whole-cell engineering approach to reconstruct complex molecules in yeast, Antheia's platform enables the discovery and manufacturing of plant-inspired drugs of unprecedented complexity and diversity. Antheia's team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about